Cardiol Therapeutics Inc.
Healthcare / Drug Manufacturers - Specialty & Generic
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Performance
--
Today 0.00 (0.00%)
CRDL
Metrics
Market Cap227M
Latest Price$1.90
Previous Close$1.85
Volume1.6M
52 Week High$2.28
52 Week Low$0.880
52 Week Change90.74%
Average Volume908K
Revenue0
EPS-0.25
P/E Ratio0
Forward P/E-8.113
Price/Book12.972
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-1.90%
Dividend Yield0.00%